ZZZiwen Zhao

Ziwen Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ziwen Zhao has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Zhuxiang Zhao

    South China Univ Technol, Dept Pulm & Crit Care Med, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China

    5 shared publications
  • Limin Xu

    Department of Geriatrics, Huizhou First People's Hospital, Huizhou, Guangdong, China

    4 shared publications
  • Changquan Fang

    Department of Pulmonary and Critical Care Medicine, Huizhou Central People's Hospital, Huizhou, Guangdong, China

    3 shared publications
  • Shuquan Wei

    South China Univ Technol, Dept Pulm & Crit Care Med, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China

    3 shared publications
  • Yujun Li

    South China Univ Technol, Dept Pulm & Crit Care Med, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China

    3 shared publications
  • Hongyi Tan

    Department of Pulmonary and Critical Care Medicine, Huizhou Central People’s Hospital, Huizhou, Guangdong, China

    2 shared publications

Latest Publications

  • Open Access

    Case Report: Chlamydia psittaci pneumonia complicated by Guillain-Barré syndrome detected using metagenomic next-generation sequencing

    by Changquan Fang, Limin Xu, Jiarong Tan, Hongyi Tan, Junhong Lin, Ziwen Zhao

    Psittacosis and Guillain-Barré syndrome are both rare clinical diseases with low incidence, and their combination has rarely been reported. Here, we report a case of Chlamydia psittaci pneumonia combined with Guillain-Barré syndrome. The patient initially presented with high fever, difficulty breathing, and fatigue. Chest computerised tomography indicated large consolidation opacities in both lungs. Metagenomic next-generation sequencing clearly identified the pathogen as C. psittaci. The patient’s fever subsided after targeted antibiotic treatment, but difficulty breathing and fatigue worsened, and the patient developed symmetric limb numbness and weakness. Lumbar puncture, electrophysiological examination, and clinical characteristics were suggestive of Guillain-Barré syndrome, and the symptoms improved after treatment with human immunoglobulin. The results of this study suggest that metagenomic next-generation sequencing is useful for the rapid diagnosis of pulmonary infectious agents. Psittacosis is closely associated with the development of Guillain-Barré syndrome; however, more cases are needed to support this conclusion, and early targeted antibiotic treatment, immunotherapy, and basic supportive treatment are essential for improving outcomes.


  • Clinical Epidemiology, Treatment, and Prognostic Factors of Hospital-Acquired Pneumonia Caused by the Extensively Drug-Resistant Acinetobacter Baumannii

    by Changquan Fang, Limin Xu, Yujun Li, Shuquan Wei, Zhuxiang Zhao, Ziwen Zhao

    Background: Extensively drug-resistant Acinetobacter baumannii (XDRAB) can acquire drug resistance genes, which are rapidly cloned and transmitted, leading to worldwide spread and posing significant treatment challenges. This study aimed to clarify effective treatment methods during XDRAB infection and factors affecting patient prognosis. Methods: Clinical features, treatment, and prognosis of 65 patients with hospital-acquired XDRAB pneumonia clinically diagnosed at Guangzhou First People's Hospital between January 2019 and December 2020 were retrospectively analyzed. Results: Of 65 subjects, only 37 survived. There was no significant difference in anti-A. baumannii activity according to type or combination of antibiotics administered between patients that survived and those that died (p > 0.05). The use of antibacterial drugs during infection did not effectively improve clinical outcomes. Advanced age, multiple organ failure, and disease severity were significantly negatively correlated while effective airway management was positively associated with bacterial clearance (p < 0.05). In multivariate analysis, age and APACHE score were independent risk factors affecting prognosis. Tracheotomy during infection was a protective factor contributing to survival (p < 0.05). Advanced age and disease severity independently affected patient prognosis, while use and type of antibacterial treatment did not substantially affect the prognosis. Conclusions: Advanced age and severe disease are independent risk factors that affect patient prognosis. Timely and effective airway management is key to improving the prognosis of patients with hospital-acquired XDRAB infection.


  • Open Access

    Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report

    by Changquan Fang, Limin Xu, Jiarong Tan, Hongyi Tan, Junhong Lin, Ziwen Zhao

    Psittacosis is a rare zoonotic disease caused by Chlamydia psittaci infection, and tetracyclines are the preferred treatment. Omadacycline is a novel tetracycline that has a strong in vitro antibacterial activity against atypical pathogens, including C. psittaci; however, clinical data for its usage are lacking. We report a patient with severe C. psittaci-induced pneumonia presenting with a high fever, muscle aches, severe hepatic and renal insufficiency, and acute respiratory failure requiring tracheal intubation and mechanical ventilation. The condition was diagnosed using metagenomic next-generation sequencing. The patient was discharged after treatment with omadacycline. The findings of this study suggest that metagenomic next-generation sequencing is valuable for the rapid and accurate diagnosis of psittacosis. With its good safety profile and no requirement for dose adjustment in special populations, omadacycline is a new option for the treatment of severe C. psittaci pneumonia. However, additional case reports are needed to support this conclusion.


  • Open Access

    Genomic features of Chinese small cell lung cancer

    by Jun Liu, Zhuxiang Zhao, Shuquan Wei, Binkai Li, Ziwen Zhao

    Background: Small cell lung cancer (SCLC) is an aggressive disease with poor survival. Although molecular and clinical characteristics have been established for SCLC in western patients, limited investigation has been performed for Chinese SCLC patients. Objective: In this study, we investigated the genomic features of Chinese SCLC patients. Methods: A total of 75 SCLC patients were enrolled. Genomic alterations in 618 selected genes were analyzed by targeted next-generation sequencing. Results: Here, we showed that TP53 (77.30%) and RB1 (30.70%) were the most prevalent genes alterations, followed by KMT2D, ALK, LRP1B, EGFR, NOTCH3, AR, CREBBP, ROS1, and BRCA2. And the most common genetic alterations were enriched in the cell cycle signaling pathway (84.00%) of Chinese SCLC patients. DNA damage repair (DDR) pathway analysis showed that the most frequently enriched DDR pathways were fanconi anaemia (FA, 29.41%) and homology recombination (HR, 21.57%). Notably, 9.33% SCLC patients in our cohort had pathogenic or likely pathogenic germline gene variants. Compared with the U Cologne cohort, a higher prevalence in EGFR, AR, BRCA2, TSC1, ATXN3, MET, MSH2, ERBB3 and FOXA1 were found in our cohort; while compared to the data from the Johns Hopkins cohort, a higher mutated frequency in TP53, KMT2D, ALK, and EGFR were found in our cohort. Moreover, a significant association was found between high tumor mutation burden (TMB) and mutations involved in TP53, CREBBP, EPHA3, KMT2D, ALK and RB1. Approximately 33.33% of patients with SCLC harbored at least one actionable alteration annotated by OncoKB, of which one patient had alterations of level 1; seventeen patients had level 3; fifteen patients possessed level 4. Conclusion: Our data might provide an insightful meaning in targeted therapy for Chinese SCLC patients.


  • Open Access

    Genomic Features of Chinese Small Cell Lung Cancer

    by Jun Liu, Zhuxiang Zhao, Binkai Li, Ziwen Zhao

    Background: Small cell lung cancer (SCLC) is an aggressive disease with poor survival. Although molecular and clinical characteristics have been established for SCLC in western patients, limited investigation has been performed for Chinese SCLC patients.Objective: In this study, we investigated the genomic features of Chinese SCLC patients.Methods: A total of 75 SCLC patients were enrolled. Genomic alterations in 618 selected genes were analyzed by targeted next-generation sequencing.Results: Here, we showed that TP53 (77.30%) and RB1 (30.70%) were the most prevalent genes, followed by KMT2D, ALK, LRP1B, EGFR, NOTCH3, AR, CREBBP, ROS1, and BRCA2. And the most common genetic alterations were enriched in the cell cycle signaling pathway (84.00%) of Chinese SCLC patients. DNA damage repair (DDR) pathway analysis showed that the most frequently enriched DDR pathways were fanconi anaemia (FA, 29.41%) and homology recombination (HR, 21.57%). Notably, 9.33% SCLC patients in our cohort had pathogenic or likely pathogenic germline gene variants. Compared with the U Cologne cohort, a higher prevalence in EGFR, AR, BRCA2, TSC1, ATXN3, MET, MSH2, ERBB3 and FOXA1 were found in our cohort; while compared to the data from the Johns Hopkins cohort, a higher mutated frequency in TP53, KMT2D, ALK, and EGFR were found in our cohort. Moreover, a significant association was found between high tumor mutation burden (TMB) and mutations involved in TP53, CREBBP, EPHA3, KMT2D, ALK and RB1. Approximately 33.33% of patients with SCLC harbored at least one actionable alteration annotated by OncoKB, of which one patient had alterations of level 1; seventeen patients had level 3; fifteen patients possessed level 4.Conclusion: Our data might provide an insightful meaning in targeted therapy for Chinese SCLC patients.

  • Open Access

    Clinical treatment of hospital-acquired pneumonia caused by extensively drug-resistant Acinetobacter baumannii: single-centre retrospective study

    by Changquan Fang, Limin Xu, Junhong Lin, Yujun Li, Shuquan Wei, Zhuxiang Zhao, Ziwen Zhao

    Background: Extensively drug-resistant Acinetobacter baumannii (XDRAB) has strong ability to acquire drug resistance genes, which are then rapidly cloned and transmitted, leading to worldwide spread posing a significant treatment challenge. Currently, limited drugs are available for the treatment of XDRAB infection, and their clinical effects are not clear; therefore, the specific factors that affect the treatment response and patient outcome require further exploration. The aim of this was to clarify effective treatment methods during XDRAB infection and the factors affecting patient prognosis according to a retrospective review of cases at our hospital.Methods: Hospital-acquired XDRAB pneumonia cases clinically diagnosed at Guangzhou First Municipal People’s Hospital from January 2016 to December 2017 were selected, and their clinical features, treatment, and prognosis were retrospectively analysed.Results: Forty-eight patients met the diagnostic criteria of hospital-acquired pneumonia caused by XDRAB in the study period, 20 of whom survived and 28 of whom died for an overall mortality rate of 58.3%. There was no significant difference in anti-A. baumannii activity according to the type of antibiotic administered or their combinations between the patients that survived and those that died from the infection. The use of antibacterial drugs during infection did not effectively improve the clinical outcome. Advanced age, multiple organ failure, and disease severity (APACHE score) were significantly negatively correlated with bacterial clearance, whereas effective airway management (tracheotomy and sputum suction during infection) had a positive impact on bacterial clearance. In multivariate analysis, age [odds ratio (OR) 1.1, 95% confidence interval (CI) 1.0–1.3] and APACHE score (OR 1.5, 95% CI 1.1–2.0) were independent risk factors affecting prognosis. Tracheotomy during infection (OR 0.0, 95% CI 0.0–0.55) was a protective factor contributing to survival.Conclusion: XDRAB hospital-acquired pneumonia has a high mortality rate. Advanced age and severe disease are independent risk factors that affect patient prognosis. The use and type of antibacterial drugs for treatment do not appear to substantially affect the prognosis during XDRAB infection. Overall, timely and effective airway management is the key to improving the prognosis of patients with hospital-acquired XDRAB infection.

  • WISP-3/CCN6 inhibits apoptosis by regulating caspase pathway after hyperoxia in lung epithelial cells

    by Shuquan Wei, Kangwei Wang, Zhuxiang Zhao, Xiaomei Huang, Wanna Tang, Ziwen Zhao


  • miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor

    by Wei Ma, Weiye Feng, Jie Tan, Airu Xu, Yudong Hu, Lanlan Ning, Yanhong Kang, Liuqian Wang, Ziwen Zhao

    Background: Recently, studies have demonstrated that microRNA-497 (miR-497) plays an important role in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in treatment of non-small cell lung cancer (NSCLC) is not fully understood. In this study, we explored the potential of miR-497 in targeting the insulin-like growth factor-1 receptor (IGF-1R) signaling pathways to overcome gefitinib resistance. Methods: A gefitinib resistant human lung adenocarcinoma A549 cell line (A549/GR) was established by the method of gefitinib mutagenesis culture. Next, the A549/GR cells were transfected with miR-497 mimics to establish an miR-497 overexpression model, designated A549/GR-miR497-mimic. MTT assay was used to assess cell resistance to gefitinib, and western blot assay was employed to evaluate alterations of IGF-1R and the AKT1 signaling pathway. Results: We found that A549/GR-miR497-mimic cells (IC50 =33.76±0.97 µmol/L) were more sensitive to gefitinib than the control group (PConclusions: We demonstrated that miR-497 may have the effect of reversing gefitinib resistance and increasing the sensitivity of NSCLC cells to EGFR-TKIs by inhibiting the expression of IGF-1R and reducing activation of the downstream AKT signaling pathway. Thus, miR-497 plays a vital role in the acquired resistance to EGFR-TKIs, and it may represent a potential therapeutic strategy to treat NSCLC exhibiting resistance to EGFR-TKIs.


  • Open Access

    Two CHRN susceptibility variants for COPD are genetic determinants of emphysema and chest computed tomography manifestations in Chinese patients

    by Zhuxiang Zhao, Changbin Jiang, Dongxing Zhao, Yujun Li, Chunxiao Liang, Weifeng Liu, Shuquan Wei, Yumin Zhou, Ziwen Zhao, Pixin Ran

    Quantitative computed tomography (CT) measures of emphysema have been shown to be associated with increased mortality in humans, but genetic variants affecting the quantitative parameters of chest CT that measure degree of emphysema have not yet been examined. In this study, using available chest CT data from a total of 344 emphysema patients, we assessed the correlations between five chronic obstructive pulmonary disease (COPD) susceptibility variants in the cholinergic receptor nicotinic (CHRN) genes and the degree of emphysema and chest CT manifestations. We verified that most of the parameters were significantly correlated with the degree of emphysema. Compared to rs76071148AA and TT genotype carriers, the rs76071148AT genotype carriers exhibited a decreased probability of having severe emphysema (odds ratio [OR] =0.63, 95% confidence interval [CI] =0.40–0.99), whereas the variant rs8040868C allele was negatively correlated with the emphysema index (P=0.002). Interestingly, further stratification analysis grouped by spirometry-diagnosed COPD status revealed that the variant rs8040868C (CT + CC) genotypes exerted a protective effect against severe emphysema with borderline significance (OR =0.41, 95% CI =0.16–1.05) and affected the mean lung density, emphysema index, ratio of airway wall thickness to airway dimensions (AWT/AD), and AWT grade in spirometry-diagnosed non-COPD subjects. The rs76071148 variant was also significantly associated with AWT/AD and AWT grade in those individuals. In summary, we determined that rs8040868 and rs76071148 are promising indicators of the degree of emphysema and chest CT manifestations, especially in spirometry-diagnosed non-COPD subjects.


  • Open Access

    Effects of a combination of amlodipine and imipenem on 42 clinical isolates of Acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China

    by Yu Jun Li, Chu Zhi Pan, Zi Wen Zhao, Zhu Xiang Zhao, Hui Ling Chen, Wei Bo Lu

    Background: The clonal spread of Acinetobacter baumannii is a global problem, and carbapenems, such as imipenem, remain the first-choice agent against A. baumannii. Using synergy to enhance the antibiotic activity of carbapenems could be useful. Here, amlodipine (AML) was tested alone and with imipenem against A. baumannii isolates. Methods: Forty-two isolates of A. baumannii were collected. Multilocus sequence typing (MLST) assessed the genetic relationship of the isolates. The resistance phenotypes were determined using disc diffusion. The minimum inhibitory concentrations (MICs) of the drugs were determined by broth microdilution. The combined effects of the drugs were determined by a checkerboard procedure. Metallo-β-lactamase (MBL) was determined using the MBL Etest. Results: Forty-two A. baumannii isolates were collected from 42 patients who were mostly older than 65 years and had long inpatient stays (≥7 days). A. baumannii was mostly recovered from the respiratory system (N = 35, 83.3%). Most patients (N = 27, 64.3%) received care in intensive care units (ICUs). Disc diffusion testing demonstrated that A. baumannii susceptibility to polymyxin B was 100%, while susceptibility to other antimicrobial agents was less than 30%, classifying the isolates into 10 MDR and 32 XDR strains. MLST grouped the A. baumannii isolates into 4 existing STs and 6 new STs. STn4 carried allele G1, with a T → C mutation at nt3 on the gpi111 locus. STn5 carried allele A1, possessing A → C mutations at nt156 and nt159 on the gltA1 locus. ST195 and ST208 accounted for 68.05% (29/42) of the isolates. Clonal relation analysis showed that ST195 and ST208 belonged to clonal complex (CC) 92. The inhibitory concentration of imipenem ranged from 0.5 to 32 μg/ml, and that of AML ranged from 40 to 320 μg/ml. In combination, the susceptibility rate of A. baumannii isolates increased from 16.7% to 54.8% (P = 0.001). In the checkerboard procedure, half of the isolates (N = 21, 50.0%) demonstrated synergy or partial synergy with the drug combination. The MBL Etest revealed that 1 A. baumannii strain (N = 1, 2.4%) produced MBL. Conclusions: CC92 was the major clone spreading in our hospital. AML improved the activity of imipenem against A. baumannii isolates in vitro but did not inhibit MBL.